Pediatric Cancers
11
1
1
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
18.2%
2 terminated out of 11 trials
75.0%
-11.5% vs benchmark
9%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (11)
Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation
Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials
NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Palliative Care and Symptom Management for the Pediatric Oncology Patient
Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA
Carotid Artery Disease in Childhood Cancer Survivors
School Reintegration Outcomes in Pediatric Cancer Patients
Parent-Delivered Massage in Paediatric Cancer
Lingzhi for Cancer Children